You searched for Adrian Towse - Page 6 of 17

We found for

Using QALYs in Cancer: Review of the Methodological Limitations

Assessment and Appraisal of Oncology Medicines: NICE’s Approach and International HTA Experience

The Market for Biosimilars: Evolution and Policy Options

Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions

Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds

Economic Post-Launch Studies: Matching the Desirable with the Feasible

Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help?

Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty

Cost-Effectiveness Thresholds: Economic and ethical issues

Influencing Prescribing in a Primary Care Led NHS

Disease Management, the NHS and the Pharmaceutical Industry

From Efficacy to Cost-Effectiveness

Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry

Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?

Economics of Innovation

Value of the Pharmaceutical Industry to the UK Economy

Financing Health Care in the UK: A Discussion of NERA’s Prototype Model to Replace the NHS

00
02
03
04
05
06
07

News & Insights

Latest Research & Publications

All Publications

We found for

Filter results by

Using QALYs in Cancer: Review of the Methodological Limitations

Assessment and Appraisal of Oncology Medicines: NICE’s Approach and International HTA Experience

The Market for Biosimilars: Evolution and Policy Options

Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions

Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds

Economic Post-Launch Studies: Matching the Desirable with the Feasible

Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help?

Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty

Cost-Effectiveness Thresholds: Economic and ethical issues

Influencing Prescribing in a Primary Care Led NHS

Disease Management, the NHS and the Pharmaceutical Industry

From Efficacy to Cost-Effectiveness

Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry

Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?

Value of the Pharmaceutical Industry to the UK Economy

Financing Health Care in the UK: A Discussion of NERA’s Prototype Model to Replace the NHS